newsfilter
← Latest News
GlobeNewswire·

Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update

Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million